Myeloproliferative Neoplasms | Specialty

The myeloproliferative neoplasms condition center is a comprehensive resource for clinical news on myeloproliferative neoplasms. Read more at OncLive.

Dr McLornan on the Future of an EBMT Machine Learning Model for Identifying and Stratifying Transplant Risk in Myelofibrosis

April 3rd 2025

Donal McLornan, MBBCh, MRCP, PhD, FRCPath, discusses future research directions for an EBMT machine learning model for identifying and stratifying transplant risk in myelofibrosis.

Dr Hernández-Boluda on an EBMT Machine Learning Model for Identifying and Stratifying Transplant Risk in Myelofibrosis

March 31st 2025

Juan Carlos Hernández-Boluda, MD, PhD, discusses an EBMT machine learning–based model for identifying and stratifying transplant risk in myelofibrosis.

Emerging Therapies in Myelofibrosis Could Extend Beyond JAK Inhibitors

March 24th 2025

Raajit Rampal, MD, PhD, discusses current JAK inhibitor treatment options for myelofibrosis and additional therapies being evaluated in clinical trials.

Five Under 5: Top Oncology Videos for the Week of 3/16

March 23rd 2025

The top 5 OncLive videos of the week cover insights in gynecologic cancer, multiple myeloma, urothelial cancer, MPNs, and prostate cancer.

Dr Bhat on the Influence of MPN Risk Stratification on Treatment Decision-Making

March 20th 2025

Seema A. Bhat, MD, discusses typical treatment decisions for patients with myeloproliferative neoplasms based on risk stratification.

Dr Rampal on ​Emerging Therapies Under Investigation in Myelofibrosis

March 17th 2025

Raajit Rampal, MD, discusses the variety of agents in phase 3 trials for the treatment of patients with myelofibrosis.

Dr Komrokji on Unanswered Questions in High-Risk MDS Management

March 12th 2025

Rami Komrokji, MD, discusses how consensus guidelines could address unanswered questions regarding the management of high-risk MDS.

Imetelstat Earns EU Approval for Transfusion-Dependent Anemia in Lower-Risk MDS

March 12th 2025

The European Commission has approved imetelstat for the treatment of patients with transfusion-dependent anemia in lower-risk myelodysplastic syndrome.

Five Under 5: Top Oncology Videos for the Week of 3/2

March 9th 2025

The top 5 OncLive videos of the week cover insights in TGCT, NSCLC, TNBC, AML, and MDS.

The OncFive: Top Oncology Articles for the Week of 3/2

March 9th 2025

Tislelizumab regimen wins approval in ESCC, perioperative durvalumab plus chemotherapy boosts EFS in gastric/GEJ cancer, and more from OncLive this week.

Ivosidenib/CPX-351 Shows Early Activity and Is Safe in IDH1-Mutated R/R AML, High-Risk MDS

March 4th 2025

Treatment with ivosidenib plus CPX-351 showed early efficacy in patients with relapsed/refractory AML or high-risk MDS harboring an IDH1 mutation.

FDA Grants Orphan Drug Designation to Bexmarilimab for Myelodysplastic Syndromes

March 4th 2025

The FDA has granted orphan drug designation to bexmarilimab for myelodysplastic syndromes.

Lisaftoclax Plus Azacitidine Shows Clinical Activity and Manageable Safety in Higher-Risk MDS

March 4th 2025

Lisaftoclax plus azacitidine demonstrated clinical activity and was safe in higher-risk MDS.

Rusfertide Meets Response End Point in Phlebotomy-Dependent Polycythemia Vera

March 3rd 2025

Rusfertide improved responses vs placebo in phlebotomy-dependent polycythemia vera.

Divesiran Is Tolerable and Shows Positive Early Signals in Polycythemia Vera

February 26th 2025

The siRNA divesiran was well-tolerated and reduced the number of phlebotomies that were required in patients with polycythemia vera.

Ruxolitinib Plus SOC Prophylaxis Is Associated With Lower Rates of GVHD in Myelofibrosis

February 14th 2025

Ruxolitinib plus standard GVHD prophylaxis reduced GVHD in patients with myelofibrosis undergoing transplant.

Dr Kishtagari on Pelabresib Plus Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis

February 13th 2025

The MANIFEST-2 trial showed that pelabresib/ruxolitinib led to greater spleen volume reduction and improved anemia vs ruxolitinib alone in myelofibrosis

MD Anderson Study Resumes With Seclidemstat/Azacitidine in MDS/CMML

February 7th 2025

The combination of seclidemstat and azacitidine will resume study in a phase 1/2 trial in patients with MDS and CMML following a partial clinical hold.

Dr Al Malki on Reducing Relapse Risk in Patients with MDS Undergoing Haplo-HSCT

February 7th 2025

Monzr M. Al Malki, MD, discusses reducing relapse risk in patients undergoing haploidentical hematopoietic stem cell transplantation.

Type II JAK Inhibitor AJ1-11095 Under Phase 1 Investigation in Myelofibrosis

February 5th 2025

AJ1-11095 is being evaluated in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia.

NEXT PAGE
PREVIOUS PAGE